<SEC-DOCUMENT>0001104659-23-116308.txt : 20231109
<SEC-HEADER>0001104659-23-116308.hdr.sgml : 20231109
<ACCEPTANCE-DATETIME>20231109162051
ACCESSION NUMBER:		0001104659-23-116308
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20231109
DATE AS OF CHANGE:		20231109
EFFECTIVENESS DATE:		20231109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aprea Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001781983
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275440
		FILM NUMBER:		231392821

	BUSINESS ADDRESS:	
		STREET 1:		3805 OLD EASTON ROAD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18902
		BUSINESS PHONE:		267-370-5219

	MAIL ADDRESS:	
		STREET 1:		3805 OLD EASTON ROAD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18902
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>tm2329846d1_s8.htm
<DESCRIPTION>FORM S-8
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">As filed with the Securities and Exchange Commission
on November&nbsp;9, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration No.&nbsp;333-_________</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;S-8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APREA THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 63%"><B>Delaware</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 35%"><B>84-2246769</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of incorporation or organization)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 68%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3805 Old Easton Road</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Doylestown, PA </B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 30%"><B>18902</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aprea Therapeutics,&nbsp;Inc. 2019 Equity Incentive
Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Full title of the plan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Oren Gilad, Ph.D.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>President and Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3805 Old Easton Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Doylestown, PA 18902</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(617) 463-9385</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address and telephone number, including
area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies t</I>o:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fahd M.T. Riaz,&nbsp;Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DLA Piper LLP (US)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>One Liberty Place</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1650 Market Street, Suite&nbsp;5000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Philadelphia, PA 19103-7300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(215) 656-3316</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large accelerated
filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 50%">Large Accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 50%">Accelerated filer <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">Non-accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD>Smaller reporting company <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>Emerging growth company <FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&nbsp;7(a)(2)(B)&nbsp;of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Part&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Information Required In The Registration Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Registration Statement
relates to the registration of an additional 106,211 shares (the &ldquo;<B><I>Shares</I></B>&rdquo;) of Aprea Therapeutics,&nbsp;Inc.
(the &ldquo;<B><I>Registrant</I></B>&rdquo;) Common Stock, par value $0.001 per share. The Shares are securities of the same class and
relate to the same employee benefit plan, the Aprea Therapeutics,&nbsp;Inc. 2019 Equity Incentive Plan (in the form attached hereto as
Exhibit&nbsp;99.1) (the &ldquo;<B><I>2019 Plan</I></B>&rdquo;), as those registered pursuant to the Registrant&rsquo;s registration statements
on Form&nbsp;S-8, previously filed with the Securities and Exchange Commission on <A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465919065133/a19-23106_1s8.htm" STYLE="-sec-extract: exhibit">November&nbsp;18, 2019 (Registration No.&nbsp;333-234765)</A>,
<A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465920124493/tm2035651-1_s8.htm" STYLE="-sec-extract: exhibit">November&nbsp;12, 2020 (Registration No.&nbsp;333-250043)</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465921135795/tm2132154d1_s8.htm" STYLE="-sec-extract: exhibit">November&nbsp;9, 2021 (Registration No.&nbsp;333-260884)</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465922127391/tm2232644d1_s8.htm" STYLE="-sec-extract: exhibit">December&nbsp;15, 2022 (Registration No.&nbsp;333-268816)</A>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with General
Instruction E of Form&nbsp;S-8, the contents of the Registrant&rsquo;s registration statements filed with the Securities and Exchange
Commission on <A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465919065133/a19-23106_1s8.htm" STYLE="-sec-extract: exhibit">November&nbsp;18, 2019 (Registration No.&nbsp;333-234765)</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465920124493/tm2035651-1_s8.htm" STYLE="-sec-extract: exhibit">November&nbsp;12, 2020 (Registration No.&nbsp;333-250043)</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465921135795/tm2132154d1_s8.htm" STYLE="-sec-extract: exhibit">November&nbsp;9, 2021 (Registration No.&nbsp;333-260884)</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465922127391/tm2232644d1_s8.htm" STYLE="-sec-extract: exhibit">December&nbsp;15, 2022 (Registration No.&nbsp;333-268816)</A> are incorporated herein by reference
(solely to the extent the contents of such registration statements relate to the 2019 Plan) and the information required by Part&nbsp;II
is omitted, except as supplemented by the information set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD><B>Item 8</B></TD>
    <TD><B>Exhibits.</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 8%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>No.</B></P></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 92%"><B>Description</B></TD></TR>
  <TR>
    <TD STYLE="text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465919053259/a19-12476_12ex3d1.htm#Exhibit3_1_102107"><FONT STYLE="color: #0000EE"><U>4.1</U></FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465919053259/a19-12476_12ex3d1.htm#Exhibit3_1_102107"><FONT STYLE="color: #0000EE">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit&nbsp;3.1 to the Registrant&rsquo;s Current Report on Form&nbsp;8-K, filed with the Commission on October&nbsp;7, 2019)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465923018997/tm236225d1_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: #0000EE">4.2</FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465923018997/tm236225d1_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: blue">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Aprea Therapeutics,&nbsp;Inc. (incorporated by reference to Exhibit&nbsp;3.1 to the Current Report on Form&nbsp;8-K filed on February&nbsp;13, 2023)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/tm2215660d3_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: #0000EE"><U>4.3</U></FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000110465922061599/tm2215660d3_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: blue">Certificate of Designation of Series&nbsp;A Non-Voting Series&nbsp;A Convertible Preferred Stock (incorporated by reference to Exhibit&nbsp;3.1 to the Current Report on Form&nbsp;8-K filed on May&nbsp;17, 2022)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000155837020013179/apre-20200930ex31ca25522.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: #0000EE"><U>4.4</U></FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000155837020013179/apre-20200930ex31ca25522.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: #0000EE">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit&nbsp;3.1 to the Registrant's Quarterly Report on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2020, filed with the Commission on November&nbsp;6, 2020)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="text-align: center"><A HREF="tm2329846d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: #0000EE"><U>5.1*</U></FONT></A></TD>
    <TD><A HREF="tm2329846d1_ex5-1.htm" STYLE="-sec-extract: exhibit">Opinion of DLA Piper LLP (US).</A></TD></TR>
  <TR>
    <TD STYLE="text-align: center"><A HREF="tm2329846d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: #0000EE"><U>23.1*</U></FONT></A></TD>
    <TD><A HREF="tm2329846d1_ex23-1.htm" STYLE="-sec-extract: exhibit">Consent of Ernst&nbsp;&amp; Young LLP</A></TD></TR>
  <TR>
    <TD STYLE="text-align: center"><A HREF="tm2329846d1_ex5-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: #0000EE"><U>23.2*</U></FONT></A></TD>
    <TD><A HREF="tm2329846d1_ex5-1.htm" STYLE="-sec-extract: exhibit">Consent of DLA Piper LLP (US) (included in Exhibit&nbsp;5.1).</A></TD></TR>
  <TR>
    <TD STYLE="text-align: center"><A HREF="#a_001"><FONT STYLE="color: #0000EE"><U>24</U></FONT></A></TD>
    <TD><A HREF="#a_001">Power of Attorney (contained on the signature page&nbsp;hereto).</A></TD></TR>
  <TR>
    <TD STYLE="text-align: center"><A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000104746919005499/a2239779zex-10_1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: #0000EE"><U>99.1</U></FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1781983/000104746919005499/a2239779zex-10_1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: #0000EE">Aprea Therapeutics,&nbsp;Inc. 2019 Equity Incentive Plan (incorporated by reference to Exhibit&nbsp;10.1 to the Registrant&rsquo;s Registration Statement (Form&nbsp;S-1/A), filed with the Commission on September&nbsp;27, 2019)</FONT></A></TD></TR>
  <TR>
    <TD STYLE="text-align: center"><A HREF="tm2329846d1_ex-filingfees.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="color: #0000EE"><U>107*</U></FONT></A></TD>
    <TD><A HREF="tm2329846d1_ex-filingfees.htm" STYLE="-sec-extract: exhibit">Filing Fee Table</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD>*</TD>
    <TD>Filed herewith</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form&nbsp;S-8 and has duly caused this Registration Statement with respect to the Aprea Therapeutics,&nbsp;Inc. 2019 Equity
Incentive Plan, to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Doylestown, State of Pennsylvania,
on November&nbsp;9, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2"><B>Aprea Therapeutics,&nbsp;Inc.</B></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD>
    </TR>
  <TR>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Oren Gilad</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR>
    <TD>Name:</TD>
    <TD>Oren Gilad, Ph.D.</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR>
    <TD>Title:</TD>
    <TD>President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The officers and directors
of Aprea Therapeutics,&nbsp;Inc. whose signatures appear below hereby constitute and appoint Oren Gilad and John Hamill, and each of them,
their true and lawful attorneys and agents, with full power of substitution, each with power to act alone, to sign and execute on behalf
of the undersigned this Registration Statement on Form&nbsp;S-8 with respect to the Aprea Therapeutics,&nbsp;Inc. 2019 Equity Incentive
Plan, and any amendment or amendments thereto, and each of the undersigned does hereby ratify and confirm all that each attorney and agent,
or his or her substitutes, shall do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 30%; font-size: 10pt; text-align: center"><B>Signature</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt; text-align: center"><B>Title</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 26%; font-size: 10pt; text-align: center"><B>Date</B></TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Oren Gilad</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">President, Chief Executive Officer and Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">November&nbsp;9, 2023</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">Oren Gilad, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(Principal Executive Officer)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ John P. Hamill</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Senior Vice President, Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">November&nbsp;9, 2023</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">John P. Hamill</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(Principal Financial and Accounting Officer)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Marc Duey</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">November&nbsp;9, 2023</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">Marc Duey</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Michael Grissinger</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">November&nbsp;9, 2023</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">Michael Grissinger</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ John B. Henneman</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">November&nbsp;9, 2023</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">John B. Henneman III</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Rifat Pamukcu</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">November&nbsp;9, 2023</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">Rifat Pamukcu, M.D.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Richard Peters</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">November&nbsp;9, 2023</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">Richard Peters, M.D., Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Gabriel Gruia</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">November&nbsp;9, 2023</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">Gabriel Gruia, M.D.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Bernd Seizinger</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">Director</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">November&nbsp;9, 2023</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">Bernd R. Seizinger, M.D., Ph.D.</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Jean-Pierre Bizzari</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">Director</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">November&nbsp;9, 2023</TD></TR>
  <TR>
    <TD STYLE="font-size: 10pt">Jean-Pierre Bizzari, M.D.</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>tm2329846d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><IMG SRC="tm2329846d1_ex5-1img002.jpg" ALT="">&nbsp;</TD>
  <TD STYLE="vertical-align: bottom; width: 50%; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">DLA Piper LLP (US)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">One Liberty Place</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">1650 Market Street, Suite&nbsp;5000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Philadelphia, PA 19103-7300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">www.dlapiper.com</P>
</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November&nbsp;9, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Aprea Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">3805 Old Easton Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Doylestown, PA 18902</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">RE: <U>Aprea Therapeutics,&nbsp;Inc.
- Registration Statement on Form&nbsp;S-8</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel to
Aprea Therapeutics,&nbsp;Inc., a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the preparation of a Registration
Statement on Form&nbsp;S-8 (the &ldquo;Registration Statement&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;).
The Registration Statement relates to the registration of an aggregate of 106,211 shares (the &ldquo;Plan Shares&rdquo;) of the Company&rsquo;s
common stock, par value $0.001 per share, issuable under the Aprea Therapeutics,&nbsp;Inc. 2019 Equity Incentive Plan (the &ldquo;Plan&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this opinion
letter, we have examined the Registration Statement and originals, or copies certified or otherwise identified to our satisfaction, of
the Amended and Restated Certificate of Incorporation, as amended and the Amended and Restated Bylaws of the Company and such other documents,
records and other instruments as we have deemed appropriate for purposes of the opinion set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have assumed the genuineness
of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity
with the originals of all documents submitted to us as certified, facsimile or photostatic copies and the authenticity of the originals
of all documents submitted to us as copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon the foregoing,
we are of the opinion that the Plan Shares have been duly authorized and, when and to the extent issued in accordance with the terms of
the Plan and any award agreement entered into under the Plan, the Plan Shares will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The opinion expressed herein
is limited to the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the use
of this opinion as Exhibit&nbsp;5.1 to the Registration Statement. In giving such consent, we do not hereby admit that we are acting within
the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules&nbsp;or regulations of the U.S. Securities
and Exchange Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">Very truly yours,</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">/s/ DLA Piper LLP (US)</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tm2329846d1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT&nbsp;23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the incorporation by reference in the Registration Statement
(Form&nbsp;S-8) pertaining to the Aprea Therapeutics,&nbsp;Inc. 2019 Equity Incentive Plan of our report dated March&nbsp;30, 2023, with
respect to the consolidated financial statements of Aprea Therapeutics,&nbsp;Inc. included in its Annual Report (Form&nbsp;10-K) for the
year ended December&nbsp;31, 2022, filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Ernst&nbsp;&amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Iselin, New Jersey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November&nbsp;8, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>tm2329846d1_ex-filingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;S-8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Form&nbsp;Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aprea Therapeutics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Table 1: Newly Registered Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border: black 1.5pt solid; width: 10%; font-size: 10pt; text-align: center"><B>Security Type</B></TD>
    <TD STYLE="border-top: black 1.5pt solid; width: 23%; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Security</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Class</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Title</B></P></TD>
    <TD STYLE="border-top: black 1.5pt solid; width: 17%; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fee</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rule</B></P></TD>
    <TD STYLE="border-top: black 1.5pt solid; width: 9%; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registered<FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></B></P></TD>
    <TD STYLE="border-top: black 1.5pt solid; width: 10%; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposed</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Maximum</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering Price</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Per Unit</B></P></TD>
    <TD STYLE="border-top: black 1.5pt solid; width: 12%; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Maximum</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aggregate</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering Price</B></P></TD>
    <TD STYLE="border-top: black 1.5pt solid; width: 8%; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><B>Fee Rate</B></TD>
    <TD STYLE="border-top: black 1.5pt solid; width: 11%; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registration</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fee</B></P></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; font-size: 10pt; text-align: center">Equity</TD>
    <TD STYLE="border-right: black 1.5pt solid; white-space: nowrap; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock, par value</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$0.001</P></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rule&nbsp;457(c)&nbsp;and Rule</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">457(h)</P></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center">106,211<FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center">$3.7664<FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center">$400,033.11<FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center">$0.00014760</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center">$59.04</TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; font-size: 10pt; text-align: center"><B>Total Offering Amounts</B></TD>
    <TD STYLE="border-right: black 1.5pt solid; vertical-align: top; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center">$400,033.11</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center">$59.04</TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; font-size: 10pt; text-align: center"><B>Total Fee Offsets<FONT STYLE="font-size: 10pt"><SUP>(4)</SUP></FONT></B></TD>
    <TD STYLE="border-right: black 1.5pt solid; vertical-align: top; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center">-</TD></TR>
  <TR>
    <TD COLSPAN="4" STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; font-size: 10pt; text-align: center"><B>Net Fee Due</B></TD>
    <TD STYLE="border-right: black 1.5pt solid; vertical-align: top; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center">$59.04</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">(1)</TD>
    <TD STYLE="font-size: 10pt">Pursuant to Rule&nbsp;416(a)&nbsp;under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), this Registration Statement on Form&nbsp;S-8 shall cover any additional shares of common stock, $0.001 par value per share (&ldquo;Common Stock&rdquo;) of the Registrant that become issuable under the Aprea Therapeutics,&nbsp;Inc. 2019 Equity Incentive Plan (the &ldquo;2019 Plan&rdquo;) by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected without the Registrant&rsquo;s receipt of consideration which results in an increase in the number of the outstanding shares of Common Stock.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">(2)</TD>
    <TD STYLE="font-size: 10pt">Consists of shares of Common Stock under the 2019 Plan.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">(3)</TD>
    <TD STYLE="font-size: 10pt">Estimated solely for the purpose of calculating the registration fee pursuant to Rules&nbsp;457(c)&nbsp;and 457(h)&nbsp;of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant&rsquo;s Common Stock as reported on the Nasdaq on November&nbsp;3, 2023.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">(4)</TD>
    <TD STYLE="font-size: 10pt">The Registrant does not have any fee offsets.</TD></TR>
  </TABLE>









<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2329846d1_ex5-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2329846d1_ex5-1img002.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !4 (T# 2(  A$! Q$!_\0
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MZT)-6>\\*W/BR3Q)'XAUCP18W,>EVL&FZA9W$-OX;NP^H_9X5NE4SO!^8/\
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I8=7_ %O=O\3]^222]%^2_P A:***8PHHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
